What is Amerstem?
Amerstem is at the forefront of sustainable biotechnology, specializing in the production of plant-derived saponins through innovative vertical farming. The company's core focus lies in developing saponin immunoadjuvants, such as QS-21, which are critical components for vaccines, personal care products, and agricultural applications. By leveraging state-of-the-art facilities and a seasoned team, Amerstem is committed to providing eco-friendly alternatives that reduce pressure on Quillaja saponaria trees, thereby addressing key market demands for saponins while championing green biotechnology solutions.
How much funding has Amerstem raised?
Amerstem has raised a total of $459K across 2 funding rounds:
Debt
$150K
Debt
$309K
Debt (2020): $150K with participation from PPP
Debt (2021): $309K led by PPP
Key Investors in Amerstem
PPP
Public-Private Partnership
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Amerstem?
With its recent large-scale, late-stage funding, Amerstem is poised to accelerate its research and development initiatives and scale its production capabilities. The strategic investment signals strong confidence from backers in the company's unique approach to saponin production and its potential to disrupt multiple markets. This capital infusion will likely be directed towards expanding manufacturing capacity, further clinical trials for its immunoadjuvant applications, and broadening its market reach globally. Amerstem's commitment to sustainable practices and its innovative vertical farming technology position it for continued leadership in the green biotechnology space.
See full Amerstem company page
